Tag: Julia C. Owens
Millendo Therapeutics begins human trial of VMS drug candidate MLE-301
Millendo Therapeutics has started a phase 1 clinical trial of its selective neurokinin 3 receptor (NK3R) antagonist MLE-301, which is being developed for the treatment ... Read More
Millendo Therapeutics wraps up merger with OvaScience
Millendo Therapeutics, a clinical-stage biopharma company engaged in developing drugs for orphan endocrine diseases, has wrapped up a previously announced merger with OvaScience, a Massachusetts-based ... Read More